Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Passage Bio (Nasdaq: PASG) has appointed Dr. William Chou as CEO, effective immediately. Dr. Chou, an experienced executive with a background in gene therapies, succeeds interim CEO Edgar Cale, who will remain as general counsel. The leadership change aims to enhance the company’s focus on developing transformative therapies for central nervous system disorders. Dr. Chou is expected to leverage his expertise to advance ongoing clinical programs and establish the company as a leader in genetic medicine.
Passage Bio (NASDAQ: PASG) announced that CFO Simona King will present at the Chardan Genetic Medicines Conference from October 3-4, 2022, in New York City. The presentation will be a fireside chat on October 3 at 1:00 p.m. ET, and it will be accessible via live webcast on their Investors & Media page. Passage Bio focuses on developing therapies for central nervous system disorders and is advancing multiple clinical programs aimed at conditions like GM1 gangliosidosis and Krabbe disease. More details can be found on their official website.
Passage Bio (Nasdaq: PASG) announced the grant of 54,000 stock options to new employees as part of their employment inducements. The options have an exercise price of $2.20 per share, matching the stock's closing price on August 15, 2022. Vesting occurs over four years, with 25% vesting after one year and the remainder in monthly installments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Passage Bio's commitment to attracting talent in the competitive biotech sector.
Passage Bio (Nasdaq: PASG) announced the dosing of the first patient in its Phase 1/2 upliFT-D clinical trial for PBFT02, a gene therapy for frontotemporal dementia (FTD) with granulin mutations. This milestone is significant for advancing PBFT02, which aims to address the unmet need for effective treatments in FTD with no approved disease-modifying therapies. The trial evaluates the safety and tolerability of a single AAV-delivered dose of PBFT02. The U.S. FDA has granted Fast Track and Orphan Drug designations for this innovative therapy.
Passage Bio, a clinical-stage genetic medicines company, will have CFO Simona King participate in a virtual panel at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:35 a.m. ET. The panel discussion, titled "Headspace - Updates in CNS Gene Therapy," will focus on advances in gene therapy for central nervous system disorders. A live webcast will be available on their website and a replay will be accessible for 30 days post-event. Passage Bio is dedicated to developing therapies for CNS diseases with limited treatment options, and is advancing three clinical programs in notable disorders.
Passage Bio (NASDAQ: PASG) has advanced its Imagine-1 clinical trial for GM1 gangliosidosis, now in the final cohort, following Independent Data Monitoring Committee recommendations. The company presented promising long-term clinical data at ASGCT and received IND clearance for PBML04 for metachromatic leukodystrophy. As of June 30, 2022, cash reserves were $239.3 million, sufficient to fund operations into Q2 2024. The company reported a net loss of $39.5 million for Q2 2022, an improvement from $48.4 million the previous year.
Passage Bio (NASDAQ: PASG) will host a conference call on August 4, 2022, at 8:30 a.m. ET to discuss its Q2 2022 financial results and business updates. The call aims to provide insights into the company's advancements in developing gene therapies for central nervous system (CNS) disorders, including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Passage Bio has established collaborations with the University of Pennsylvania's Gene Therapy Program to enhance its clinical pipeline. An archived webcast will be available following the event.
Passage Bio (Nasdaq: PASG) announced on July 21, 2022, the granting of inducement awards to new employees, including options to purchase 85,500 shares of common stock at an exercise price of $2.16 per share. These stock options will vest over four years, with 25% vesting after one year and the remainder in 36 monthly installments, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent in the clinical-stage genetic medicines sector, particularly focused on CNS disorders.
Passage Bio (Nasdaq: PASG) announced the appointment of Dr. Michael Kamarck to its board of directors and the Nominating and Corporate Governance Committee. Dr. Kamarck brings over 40 years of experience in biopharmaceuticals, including leadership roles in manufacturing and technical operations. His previous positions include Chief Technology Officer at Vir Biotechnology and Senior Vice President at Merck. The company is focused on developing genetic therapies for CNS disorders and has established a collaboration with the University of Pennsylvania. Dr. Kamarck's expertise is expected to enhance Passage Bio's clinical programs.
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, announced that CFO Simona King will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference from June 13-16, 2022. The event, scheduled for June 16 at 8:40 a.m. PT (11:40 a.m. ET), will be webcast live on the company’s website. Passage Bio focuses on developing transformative therapies for central nervous system disorders and is advancing clinical programs for conditions like GM1 gangliosidosis and Krabbe disease.